Treatment with calcium antagonists has been shown to be beneficial in patients with primary and secondary Raynaud's phenomenon. A double-blind placebo-controlled crossover trial was performed to assess the efficacy of amlodipine, a new long-acting calcium antagonist, in patients with Raynaud's phenomenon without underlying disease. 20 of the 24 patients enrolled (20 women and 4 men, mean age 45 years) completed the trial. The number of episodes of Raynaud's phenomenon per week and the severity of discomfort significantly improved during amlodipine (p < 0.0001 and p < 0.0004, respectively) but not placebo treatment. Perfusion-pressure index, evaluated with Doppler sonography using a postischaemia reactive hyperaemia test, significantly improved (p < 0.04) after treatment with amlodipine but not placebo. These results indicate that amlodipine is a useful treatment for primary and suspected secondary Raynaud's phenomenon, at least in the short term.

Amlodipine in the treatment of Raynaud's phenomenon. A double blind placebo-controlled crossover study / La Civita, L.; Pitaro, N.; Rossi, M.; Giuggioli, D.; Gambini, I.; Cini, G.; Pasero, G.; Ferri, C.. - In: CLINICAL DRUG INVESTIGATION. - ISSN 1173-2563. - 13:1(1997), pp. 126-131.

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Powered by IRIS-about IRIS-Utilizzo dei cookie

 Copyright © 2021